Program
Anti-TROP2 Antibody-drug Conjugate ESG401
Its studies are mostly in Breast Neoplasms · Triple Negative Breast Neoplasms, led by 2 companies.
Drug pageAnti-TROP2 Antibody-drug Conjugate ESG401: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceuticalits history only | 22 open or running | phase 3since Apr 22, 2024 | Apr 22, 2024 | Jun 2027phase 3 · NCT06732323 |
| Shanghai Escugen Biotechnologyits history only | 10 open or running | phase 2since May 13, 2021 | May 13, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 13, 2021First study: phase 2 study in Breast NeoplasmsNew to Shanghai Escugen BiotechnologyShanghai Escugen Biotechnology · NCT04892342 · 156 enrolled · China
- Apr 22, 2024Qilu Pharmaceutical’s first study: phase 3 study in Breast NeoplasmsNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06383767 · 378 planned · China
- Dec 10, 2024Phase 3 study in Triple Negative Breast NeoplasmsQilu Pharmaceutical · NCT06732323 · 504 planned · China
Ahead
- Jun 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsQilu Pharmaceutical · NCT06732323
- Jun 30, 2027Primary completion: phase 3 study in Breast NeoplasmsQilu Pharmaceutical · NCT06383767
TargetBeta
“An antibody-drug conjugate (ADC) composed of sacituzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06732323Triple Negative Breast Neoplasms · China | 3 | Recruiting | Qilu Pharmaceutical | Jun 2027 | 504 |
| NCT06383767Breast Neoplasms · China | 3 | Recruiting | Qilu Pharmaceutical | Jun 30, 2027 | 378 |
| NCT04892342Breast Neoplasms · China | 2 | Completed | Shanghai Escugen Biotechnology | Jun 30, 2025 | 156 |
How it is read
Names in the registry
- “ESG401”, 3 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.